SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS)
IONS 82.71+2.2%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom jones who wrote (2073)7/16/1998 9:52:00 PM
From: DTselentis  Read Replies (1) of 4676
 
Wasn't Isis's drug granted Priority Review by the FDA because it could be a great improvement over existing therapies ? Why would the FDA not want to approve a drug if no effective therapy exists. Its seems to me that if the drug can improve on existing therapies----even in a relatively small amount of patients the FDA would look toward approval.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News